Correction: Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline- Based Germline Testing (JAMA - Journal of the American Medical Association (2017) 318:9 (825-835) DOI: 10.1001/jama.2017.11137);Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing

JAMA - Journal of the American Medical Association

Volumn 318, Issue 9, 2017, Pages 825-835

  Mandelker, Diana ^a   Zhang, Liying ^a   Kemel, Yelena ^a   Stadler, Zsofia K ^a,b   Joseph, Vijai ^a,b   Zehir, Ahmet ^a   Pradhan, Nisha ^a   Arnold, Angela ^a   Walsh, Michael F ^a,b   Li, Yirong ^a   Balakrishnan, Anoop R ^a   Syed, Aijazuddin ^a   Prasad, Meera ^a   Nafa, Khedoudja ^a   Carlo, Maria I ^a,b   Cadoo, Karen A ^a,b   Sheehan, Meg ^a   Fleischut, Megan H ^a   Salo Mullen, Erin ^a   Trottier, Magan ^a   Lipkin, Steven M ^b   Lincoln, Anne ^a   Mukherjee, Semanti ^a   Ravichandran, Vignesh ^a   Cambria, Roy ^a   Galle, Jesse ^a   Abida, Wassim ^a,b   Arcila, Marcia E ^a   Benayed, Ryma ^a   Shah, Ronak ^a   Yu, Kenneth ^a,b   Bajorin, Dean F ^a,b   Coleman, Jonathan A ^a,b   Leach, Steven D ^a,b   Lowery, Maeve A ^a,b   Garcia Aguilar, Julio ^a,b   Kantoff, PhilipW ^a,b   Sawyers, Charles L ^a,b   Dickler, Maura N ^a,b   Saltz, Leonard ^a,b   Motzer, Robert J ^b   O'Reilly, Eileen M ^a,b   Scher, Howard I ^a,b   Baselga, Jose ^a,b   Klimstra, David S ^a,b   Solit, David B ^a,b   Hyman, David M ^a,b   Berger, Michael F ^a,b   Ladanyi, Marc ^a   Robson, Mark E ^a,b   Offit, Kenneth ^a,b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE TARGETING; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; GENOMICS; GERMLINE MUTATION; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GENE; DNA MUTATIONAL ANALYSIS; GENETICS; MIDDLE AGED; NEOPLASM; PHENOTYPE; PROCEDURES; PROSPECTIVE STUDY;

DNA; TUMOR MARKER;

AGED; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; PROSPECTIVE STUDIES;

EID: 85028943584     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2018.17511     Document Type: Erratum

References (38)

1. Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. JAMA Oncol. 2016;2(1):104-111.
2. Seifert BA, O'Daniel JM, Amin K, et al. Germline analysis from tumor-germline sequencing dyads to identify clinically actionable secondary findings. Clin Cancer Res. 2016;22(16):4087-4094.
3. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med. 2015;7(283):283ra53.
4. Parsons DW, Roy A, Yang Y, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616-624.
5. Mody RJ, Wu Y-M, Lonigro RJ, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314(9):913-925.
6. Meric-Bernstam F, Brusco L, Daniels M, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol. 2016;27(5):795-800.
7. Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336-2346.
8. Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL; Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015;17(1):70-87.
9. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2017. September 19, 2016. https://www.nccn.org/professionals/physician-gls/pdf/genetics-screening.pdf. Accessed September 23, 2016.
10. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2016. September 26, 2016. https://www.nccn.org/professionals/physician-gls/pdf/genetics-colon. pdf. Accessed September 23, 2016.
11. Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251-264.
12. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients. Nat Med. 2017;23(6):703-713.
13. Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302-308.
14. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19(2):249-255.
15. Cheng DT, Prasad M, Chekaluk Y, et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med Genomics. 2017;10(1):33.
16. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443-453.
17. AbidaW, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017; (1): 1-16. doi:10.1200/PO.17.00029
18. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
19. Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44(16):e131.
20. Niu B, Ye K, Zhang Q, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics. 2014;30(7):1015-1016.
21. UpToDate. Search. https://www.uptodate.com/contents/search. Accessed October 19, 2016.
22. American Society of Clinical Oncology. Cancer Genetics Program. http://university.asco.org/cancer-genetics-program. Accessed October 19, 2016.
23. Menko FH, van Steensel M A M, Giraud S, et al; European BHD Consortium. Birt-Hogg-Dubé syndrome: diagnosis and management. Lancet Oncol. 2009;10(12):1199-1206.
24. Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177-182.
25. Thakker RV, Newey PJ, Walls GV, et al; Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011.
26. Exome Aggregation Consortium. ExAC Browser Beta. http://exac.broadinstitute.org/about. Accessed August 24, 2016.
27. Lek M, Karczewski KJ, Minikel EV, et al; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60, 706 humans. Nature. 2016;536(7616):285-291.
28. International Genome Sample Resource. IGSR and the 1000 Genomes Project. http://www.internationalgenome.org/. Accessed August 24, 2016.
29. National Center for Biotechnology Information. dbSNP Short Genetic Variations. https://www.ncbi.nlm.nih.gov/projects/SNP/. Accessed August 24, 2016.
30. IBD Exomes Portal. IBD Exomes browser. https://ibd.broadinstitute.org/. Accessed October 5, 2016.
31. American Cancer Society. Cancer facts and figures 2016. https://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed December 19, 2016.
32. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(database issue):D805-D811.
33. Wellcome Trust Sanger Institute Genome Research Ltd. COSMIC: Catalogue of Somatic Mutations in Cancer. http://cancer.sanger.ac.uk/cosmic. Accessed August 24, 2016.
34. Bombard Y, Robson M, Offit K. Revealing the incidentalome when targeting the tumor genome. JAMA. 2013;310(8):795-796.
35. Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003;95(9):669-674.
36. Ng A J M, Walia MK, Smeets MF, et al. The DNA helicase RECQL4 is required for normal osteoblast expansion and osteosarcoma formation. PLoS Genet. 2015;11(4):e1005160.
37. Wang LL, Plon SE. Rothmund-Thomson syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al, eds. Gene Reviews. Seattle, WA: University of Washington; 1993.
38. Offit K. The future of clinical cancer genomics. Semin Oncol. 2016;43(5):615-622.